Link to publications​

PEER Reviewed Journal Publications

1. Tingting Weng, Junsuk Ko, Chioniso P. Masamha, Zheng Xia, Yu Xiang, Ning-yuan Chen, Jose G. Molina, Scott Collum, Tinne C. Mertens, Fayong Luo, Kemly Philip, Jonathan Davies, Jingjing Huang, Cory Wilson, Rajarajan A. Thandavarayan, Brian A. Bruckner, Soma S.K. Jyothula, Kelly A. Volcik, Lei Li, Leng Han, Wei Li, Shervin Assassi, Harry Karmouty-Quintana, Eric J. Wagner, and Michael R. Blackburn. 2019. Cleavage factor 25 deregulation contributes to pulmonary fibrosis through alternative polyadenylation The Journal of Clinical Investigations. 2019 Feb 28; 130. pii: 122106. doi: 10.1172/JCI122106.

2. Hyun Jung Park, Ping Ji, Soyeon Kim, Zheng Xia, Benjamin Rodriguez, Lei Li, Jianzhong Su, Kaifu Chen, Chioniso P. Masamha ,David Baillat, Camilla R. Fontes, Ann-Bin Shyu, Joel R. Neilson, Eric J. Wagner ,Wei Li, 2018. 3ʹ-UTR Shortening Represses Tumor Suppressor Genes in trans by Disrupting ceRNA Crosstalk#. Nature Genetics 50,783-789. DOI: 10.1038/s41588-018-0118-8. # Manuscript was highlighted in Science Daily article “New data changes the way scientists explain how cancer tumors develop.”

3. Chioniso P. Masamha* and Patrick LaFontaine. 2018. Molecular targeting of glutaminase sensitizes metastatic, cisplatin resistant ovarian cancer to chemotherapy. Journal of Cellular Biochemistry. 119:6136– 6145. doi: *Corresponding/Senior author.

4. Masamha, C. P*., Todd, Z. Adapting 3′ Rapid Amplification of CDNA Ends to Map Transcripts in Cancer#. 2018. Journal of Visualized Experiments (JoVE) 133, e57318, doi: 10.3791/57318 (2018). *Corresponding/Senior author. #Manuscript is accompanied with a video that also features two mentees Todd Z (MS student) and Gibbs (PharmD 2019) demonstrating different protocols in the lab.

5. Benbrook DM, Janakiram NB, Chandra V, Pathuri G, Madka V, Stratton NC, Masamha CP, Farnsworth CN, Garcia-Contreras L, Hatipoglu MK, Lighfoot S, Rao CV. Development of a dietary formulation of the SHetA2 chemoprevention drug for mice. Investigational New Drugs. 2017 Dec 22. doi: 10.1007/s10637- 017-0550-0. [Epub ahead of print].

6. Masamha Chioniso P. * and Eric. J. Wagner*. The contribution of alternative polyadenylation to the cancer phenotype. 2017. Carcinogenesis. 2017 Sep 11. doi: 10.1093/carcin/bgx096 *Co-corresponding/Senior authors. 

7. Masamha Chioniso Patience*. The drive to generate multiple forms of oncogenic cyclin D1 transcripts in mantle cell lymphoma. Journal of Biomarker Research. 2017. May 8; 5:16. DOI: 10.1186/s40364-017- 0094-7. eCollection 2017. *Co-corresponding/Senior author.

8. Masamha C.P., Xia Z, Peart N, Collum S, Li W, Wagner E.J., Shyu A.B. CFIm25 regulates glutaminase alternative terminal exon definition to modulate miR-23 function. RNA. 2016; 22(6):830-8. PMID: 27095025.

9. Masamha C.P*., Albrecht T, Wagner E.J. *2016. Discovery and characterization of a novel CCND1/MRCK gene fusion in mantle cell lymphoma. Journal of Hematology & Oncology 20169:30. DOI: 10.1186/s13045-016-0260-7 . *Co-corresponding/Senior authors.

10. Masamha C.P., Xia Z., Yang,J., Albrecht T.R., Li,M., Shyu A-B., Li W., and Wagner, E.J. 2014. CFIm25 links Alternative Polyadenylation to Glioblastoma Tumor Suppression. Nature. 510, 412–416 (19 June 2014) doi:10.1038/nature13261. #This article was the focus of a Research Highlight commentary in Cell Research entitled “Driving glioblastoma growth by alternative polyadenylation”. Ting Han and John K Kim. Cell Research (2014) 24:1023–1024. doi:10.1038/cr.2014.88; published online 4 July 2014.

11. Benbrook D.M*, Masamha C.P*. 2011. The pro-survival function of Akt kinase can be overridden or converted into a pro-apoptotic function. Current Cancer Drug Targets 2011:11(5). *These authors contributed equally to this manuscript.

12. Masamha C.P, Benbrook D.M. Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of Cyclin E2 in SHetA2-treated ovarian cancer cells. Cancer Research 2009: August 15;69(15) 6565-6572.

13. Liu T, Masamha C.P, Chengedza S, Berlin K.D, Lightfoot S, He F, Benbrook D.M.,2009. Development of flexible-heteroarotinoids for kidney cancer. Molecular Cancer Therapeutics; May 2009: 8(5) 1227-1238.